RepoRts

Glioblastoma multiforme (GBM) is the most common and most deadly primary brain tumor affecting adults. Despite advance-ments made in surgical, radiological and chemo-therapies for this grade IV astrocytoma, prognoses have remained very poor: median survival time from diagnosis remains at 9–15 mo, with less than 10 % of patients surviving beyond 5 y.1,2 Caveolin-1 (Cav-1) is the principle structural protein responsi-ble for the formation of caveolae, or invaginating microdomains, in the cell membrane. The capacity for Cav-1 to associate with a wide variety of proteins has implicated it in a number of processes, ranging from vesicular transport and cholesterol homeostasis to nitric oxide production and cell migration, among others.3-7 Its ability to regulate cell cycle progression and intracellular signal transduction have resulted in the substantial characterization of Cav-1 in many cancers, where it has been shown to act as both